K Schror

Summary

Affiliation: Heinrich Heine University
Country: Germany

Publications

  1. ncbi Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs
    Ralph T Schermuly
    University of Giessen Lung Center, Medical Clinic II V, Justus Liebig University Giessen, 35392 Giessen, Germany
    Respir Res 8:4. 2007
  2. ncbi Comparative pharmacology of GP IIb/IIIa antagonists
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat Dusseldorf, Germany
    J Thromb Thrombolysis 15:71-80. 2003
  3. ncbi Aspirin resistance - does it clinically matter?
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Heinrich Heine Universitat, Universitatsstr 1, Geb 22 21, 40225, Dusseldorf, Germany
    Clin Res Cardiol 95:505-10. 2006
  4. ncbi [Haemostasis and antithrombotic drugs: pharmacology and novel therapeutic approaches]
    K Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat Dusseldorf, Moorenstr 5, 40225 Dusseldorf
    Hamostaseologie 26:104-5. 2006
  5. ncbi Aspirin "resistance"
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Heinrich Heine Universitat, Universitatsstr 1, Geb 22 21, D 40225 Dusseldorf, Germany
    Blood Cells Mol Dis 36:171-6. 2006
  6. ncbi [Haemostaseology]
    K Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Germany
    Internist (Berl) 46:873-8, 880-1. 2005
  7. ncbi Cardiovascular risk of selective cyclooxygenase-2 inhibitors
    Karsten Schror
    Department of Pharmacology and Clinical Pharmacology, University of Dusseldorf, Germany
    J Cardiovasc Pharmacol Ther 10:95-101. 2005
  8. ncbi The pharmacology of cilostazol
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat, Dusseldorf, Germany
    Diabetes Obes Metab 4:S14-9. 2002
  9. ncbi [Current pharmacological principles to inhibit platelet function and their clinical implications. Focus on clopidogrel]
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum, Heinrich Heine Universitat Dusseldorf
    Med Klin (Munich) 99:3-7. 2004
  10. ncbi Mechanisms of anti-ischemic action of prostaglandin E1 in peripheral arterial occlusive disease
    K Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Heinrich Heine Universitat, Germany
    Vasa 33:119-24. 2004

Collaborators

Detail Information

Publications70

  1. ncbi Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs
    Ralph T Schermuly
    University of Giessen Lung Center, Medical Clinic II V, Justus Liebig University Giessen, 35392 Giessen, Germany
    Respir Res 8:4. 2007
    ..The rapid desensitization of the human prostacyclin (IP) in response to agonist binding has been shown in cell culture. Phosphorylation of the IP receptor by protein kinase C (PKC) has been suggested to be involved in this process...
  2. ncbi Comparative pharmacology of GP IIb/IIIa antagonists
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat Dusseldorf, Germany
    J Thromb Thrombolysis 15:71-80. 2003
    ..The inherent problems with all GP IIb/IIIa antagonists are the narrow therapeutic range because the same mechanisms are involved in hemostasis and thrombosis and their inability to inhibit platelet activation...
  3. ncbi Aspirin resistance - does it clinically matter?
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Heinrich Heine Universitat, Universitatsstr 1, Geb 22 21, 40225, Dusseldorf, Germany
    Clin Res Cardiol 95:505-10. 2006
    ..At this time,there is no reason to change there commended daily maintenance dose of about 100 mg ASA without particular requirements in patients who need coronary protection...
  4. ncbi [Haemostasis and antithrombotic drugs: pharmacology and novel therapeutic approaches]
    K Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat Dusseldorf, Moorenstr 5, 40225 Dusseldorf
    Hamostaseologie 26:104-5. 2006
    ..From a pharmacological point of view these compounds are likely to improve and enlarge the spectrum of available antiplatelet and antithrombotic drugs, respectively...
  5. ncbi Aspirin "resistance"
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Heinrich Heine Universitat, Universitatsstr 1, Geb 22 21, D 40225 Dusseldorf, Germany
    Blood Cells Mol Dis 36:171-6. 2006
    ..In this context, it is interesting that CABG patients express transiently an immunoreactive COX-2 protein with lower molecular weight. Studies on the significance of this finding for ASA resistance are in progress...
  6. ncbi [Haemostaseology]
    K Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Germany
    Internist (Berl) 46:873-8, 880-1. 2005
    ..Despite of this optimistic outlook, the individual risk/benefit ratio of these new drugs, in particular in the area of anticoagulants, still needs to be defined...
  7. ncbi Cardiovascular risk of selective cyclooxygenase-2 inhibitors
    Karsten Schror
    Department of Pharmacology and Clinical Pharmacology, University of Dusseldorf, Germany
    J Cardiovasc Pharmacol Ther 10:95-101. 2005
    ..We summarize the mechanisms of actions of this class of agents, their cardiovascular risk as evident in multiple trials, the basis of their adverse risk profile, and our views on this issue...
  8. ncbi The pharmacology of cilostazol
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat, Dusseldorf, Germany
    Diabetes Obes Metab 4:S14-9. 2002
    ..This might result in some drug interaction, i.e. with erythromycin and omeprazole. The half-life is approximately 10 h, resulting in about 2-fold accumulation of the drug during repeated administration...
  9. ncbi [Current pharmacological principles to inhibit platelet function and their clinical implications. Focus on clopidogrel]
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum, Heinrich Heine Universitat Dusseldorf
    Med Klin (Munich) 99:3-7. 2004
    ..There is neither a generally accepted definition of insufficient responsiveness (against inhibitors of platelet function) nor any generally accepted procedure to measure it, including definition of normal range...
  10. ncbi Mechanisms of anti-ischemic action of prostaglandin E1 in peripheral arterial occlusive disease
    K Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Heinrich Heine Universitat, Germany
    Vasa 33:119-24. 2004
    ..Thus, regulation of gene transcription by PGE1 may contribute to tissue protection in critical ischemia of the lower limbs...
  11. ncbi [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors]
    K Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat Dusseldorf
    Herz 26:30-5. 2001
    ..However, the TARGET trial (tirofiban vs. abciximab in patients with acute coronary syndromes) is underway and probably will answer this question...
  12. ncbi Aspirin and Reye syndrome: a review of the evidence
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat Dusseldorf, Dusseldorf, Germany
    Paediatr Drugs 9:195-204. 2007
    ..Clearly, no drug treatment is without side effects. Thus, a balanced view of whether treatment with a certain drug is justified in terms of the benefit/risk ratio is always necessary. Aspirin is no exception...
  13. ncbi Oral naftidrofuryl prevents platelet hyperreactivity ex vivo and inhibits functional desensitization to prostacyclin in hypercholesterolemic rabbits
    A A Weber
    Institut fur Pharmakologie, Heinrich Heine Universitat Dusseldorf, Germany
    J Cardiovasc Pharmacol 21:332-8. 1993
    ..These data suggest beneficial effects of NAF on platelet hyperreactivity in experimental hypercholesterolemia which may also be relevant for its clinical use...
  14. ncbi Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins
    Kerstin Rabausch
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Germany
    Circ Res 96:e1-6. 2005
    ..The full text of this article is available online at http://circres.ahajournals.org...
  15. ncbi Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit
    G Kaber
    Institut für Pharmakologie und Klinische Pharmakologie der Heinrich Heine Universität, Dusseldorf, Germany
    Br J Pharmacol 164:561-9. 2011
    ..The present study specifically addresses the pharmacological interactions between selective COX-2 inhibitors and ASA and the possible consequences for the thrombotic risk during long-term treatment...
  16. ncbi Induction of hyaluronic acid synthase 2 (HAS2) in human vascular smooth muscle cells by vasodilatory prostaglandins
    M Sussmann
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat Dusseldorf, Germany
    Circ Res 94:592-600. 2004
    ..Therefore, upregulation of HAS2 expression via EP(2) and IP receptors might contribute to the accumulation of HA during human atherosclerosis, thereby mediating proatherosclerotic functions of COX2...
  17. ncbi [Experimental study of the effect of pentaerythritol tetranitrate in acute myocardial infarct]
    T Hohlfeld
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat, Dusseldorf
    Herz 25:694-702. 2000
    ..Therefore, PETN reduced infarct size and improved myocardial function after LAD occlusion and reperfusion. It is concluded that the intravenous administration of PETN might be of advantage in the treatment of acute myocardial ischemia...
  18. ncbi Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation
    T Ulrych
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Dusseldorf, Germany
    J Thromb Haemost 9:790-8. 2011
    ..Platelets release the immune-modulating lipid sphingosine-1-phosphate (S1P). However, the mechanisms of platelet S1P secretion are not fully understood...
  19. ncbi Antiatherosclerotic effects of oral naftidrofuryl in cholesterol-fed rabbits involve inhibition of neutrophil function
    P Kienbaum
    Institut fur Pharmakologie, Heinrich Heine Universitat Dusseldorf, Germany
    J Cardiovasc Pharmacol 25:774-81. 1995
    ..These data demonstrate significant endothelium-protective actions of long-term oral naftidrofuryl in cholesterol-fed rabbits that involve inhibition of cholesterol-induced neutrophil activation...
  20. ncbi Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers
    Artur Aron Weber
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Germany
    Platelets 18:379-85. 2007
    ..g. patients with advanced atherosclerotic disease) COX-2 inhibitors may result in platelet activation by inhibiting endothelial prostacyclin formation...
  21. ncbi Influence of mycophenolic acid and FK-506 on human platelet activation in vitro
    B C Klein
    Department of Nephrology and Rheumatology, Heinrich Heine University, Dusseldorf, Germany
    Kidney Blood Press Res 23:119-24. 2000
    ..The aim of this study was to evaluate the in vitro effects of MPA and FK upon platelet activation in healthy subjects...
  22. ncbi Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis
    T Hohlfeld
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum, Heinrich Heine Universitat Dusseldorf, Dusseldorf, Germany
    J Thromb Haemost 6:166-73. 2008
    ..Anti-inflammatory analgesics, including ibuprofen and naproxen, are known to interfere with the antiplatelet effect of aspirin, presumably as a result of a drug-drug interaction at the level of platelet cyclooxygenase-1 (COX-1)...
  23. ncbi Effects of fibroblast extracellular matrix calcification on platelet adhesion in vitro
    J N Kwiatkowski
    Institut fur Pharmakologie und Klinische Pharmakologie, Universittsklinikum Dusseldorf, Germany
    Platelets 19:467-70. 2008
    ..Taken together, it appears unlikely that calcification of atherosclerotic lesions contributes to thrombotic complications by an increased platelet adhesion...
  24. ncbi Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel
    A Hermann
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat, Dusseldorf, Germany
    Platelets 12:74-82. 2001
    ..In contrast, clopidogrel treatment completely abolished ADP-induced expression of CD40L. Finally, the expression level of CD40L was shown to be upregulated by phorbol myristate acetate (PMA) in the promegakaryocytic cell line MEG-01...
  25. ncbi Reduction of infarct size by selective stimulation of prostaglandin EP(3)receptors in the reperfused ischemic pig heart
    T Hohlfeld
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat Dusseldorf, Dusseldorf, D 40225, Germany
    J Mol Cell Cardiol 32:285-96. 2000
    ....
  26. ncbi Roles of vasodilatory prostaglandins in mitogenesis of vascular smooth muscle cells
    K Schror
    Institut fur Pharmakologie, Heinrich Heine Universitat Dusseldorf, Germany
    Agents Actions Suppl 48:63-91. 1997
    ..In conclusion, vasodilatory prostaglandins might be considered as growth modulating endogenous mediators in vascular smooth muscle cells...
  27. ncbi Effects of terbogrel on platelet function and prostaglandin endoperoxide transfer
    S Muck
    Institut fur Pharmakologie, Heinrich Heine Universitat, Dusseldorf, Germany
    Eur J Pharmacol 344:45-8. 1998
    ..Terbogrel appears to be a compound with an equipotent molar potency as thromboxane A2 synthase inhibitor and receptor antagonist...
  28. ncbi [Anti-integrins--new platelet function inhibitors for therapy and prevention of acute coronary syndrome]
    K Schror
    Institut fur Pharmakologie, Heinrich Heine Universitat Dusseldorf, Bundesrepublik Deutschland
    Wien Klin Wochenschr 111:90-7. 1999
    ..Whether these substances are superior to oral aspirin and/or clopidogrel in long-term prevention of acute arterial vessel occlusions remains to be determined...
  29. ncbi Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting
    Artur-Aron Weber
    , , , Moorenstrasse 5, , Germany
    Br J Haematol 117:424-6. 2002
    ..31 +/- 0.88 versus 9.15 +/- 0.88; means +/- SEM, n = 7, P < 0.05), whereas COX-1 levels did not change (13.45 +/- 1.11 versus 12.38 +/- 1.41; n = 7, P > 0.05)...
  30. ncbi Variable platelet response to aspirin in patients with ischemic stroke
    Thomas Hohlfeld
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat, Dusseldorf, Deutschland
    Cerebrovasc Dis 24:43-50. 2007
    ..It is not clear whether all of these patients with ischemic stroke respond normally to ASA or are hyporesponsive as assessed by inhibition of aggregation and thromboxane (TX) synthesis...
  31. ncbi Towards a definition of aspirin resistance: a typological approach
    Artur-Aron Weber
    , , , Germany
    Platelets 13:37-40. 2002
    ..This typology of aspirin resistance should help to clarify the mechanisms, the actual rate, and the possible clinical consequences of this phenomenon...
  32. ncbi Regulation of hyaluronan synthesis by vasodilatory prostaglandins. Implications for atherosclerosis
    Jens W Fischer
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Dusseldorf, Germany
    Thromb Haemost 98:287-95. 2007
    ..This review discusses the regulation of HA-synthesis by prostaglandins and the evidence for a central role of cyclooxygenase-2/PGE2 in regulation of HA-synthesis during atherogenesis...
  33. ncbi Prostacyclin enhances the expression of LPS/INF-gamma-induced nitric oxide synthase in human monocytes
    Jorg Plum
    Medizinische Klinik und Poliklinik, Klinik fur Nephrologie und Rheumatologie, Heinrich Heine Universitat, Moorenstrasse 5, D 40225 Dusseldorf, Germany
    Nephron 91:391-8. 2002
    ..The ability of human mononuclear cells to contribute to the NO production by expression of active inducible NO synthase (iNOS) is still discussed controversely...
  34. ncbi Validation of self-made fluorescent cyanine dyes for 2D gel-based multi-fluorescence protein analysis
    Gernot Kaber
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Universitatsstrasse 1, Dusseldorf, Germany
    Arch Physiol Biochem 115:252-8. 2009
    ..To validate the potential use as labels in 2-DE/MFA experiments, dyes were used for the differential analysis of the proteome of thrombin-stimulated human vascular smooth muscle cells (VSMCs)...
  35. ncbi Overexpression of prostaglandin EP3 receptors activates calcineurin and promotes hypertrophy in the murine heart
    Jutta Meyer-Kirchrath
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum, Heinrich Heine Universitat, Moorenstr 5, D 40225 Dusseldorf, Germany
    Cardiovasc Res 81:310-8. 2009
    ..This study focuses on the EP(3)-mediated hypertrophic action and investigates intracellular signalling pathways of the EP(3)-receptor subtype in the murine heart...
  36. ncbi Regulation of protease-activated receptor-1 by vasodilatory prostaglandins via NFAT
    Anke C Rosenkranz
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat Dusseldorf, Universitatsstrasse 1, 40225 Dusseldorf, Germany
    Cardiovasc Res 83:778-84. 2009
    ..This study examines the downstream mechanisms, particularly the role of nuclear factor of activated T-cells (NFAT)...
  37. ncbi Regulation of cyclooxygenase-2 expression by iloprost in human vascular smooth muscle cells. Role of transcription factors CREB and ICER
    Svenja Debey
    , , , Moorenstrasse 5, , Germany
    Biochem Pharmacol 65:979-88. 2003
    ..This might be important for control of hSMC proliferation, migration and differentiation as well as inhibition of platelet aggregation...
  38. ncbi Targeting phosphoprotein profiling by combination of hydroxyapatite-based phosphoprotein enrichment and SELDI-TOF MS
    Ingo Vormbrock
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitätsklinikum der Heinrich Heine Universität, Dusseldorf, Germany
    Arch Physiol Biochem 116:181-7. 2010
    ..SELDI-TOF MS analysis of the pre-fractionation eluate confirmed a considerable reduction of sample complexity and an enhancement of selected protein signals...
  39. ncbi Thrombin receptors in vascular smooth muscle cells - function and regulation by vasodilatory prostaglandins
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Universitatsstrasse 1, Gebäude 22 21, 40225 Dusseldorf, Germany
    Thromb Haemost 103:884-90. 2010
    ....
  40. ncbi Functional testing methods for the antiplatelet effects of aspirin
    Karsten Schror
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat Dusseldorf, Universitatsklinikum, Germany
    Biomark Med 5:31-42. 2011
    ....
  41. ncbi Cholesterol enhances thrombin-induced release of fibroblast growth factor-2 in human vascular smooth muscle cells
    Bernhard H Rauch
    Universitatsklinikum Dusseldorf, Institut fur Pharmakologie und Klinische Pharmakologie, Universiäts str 1, 40225 Dusseldorf, Germany
    Arterioscler Thromb Vasc Biol 27:e20-5. 2007
    ..The present study investigates possible effects of cholesterol enrichment and depletion, which have been shown to influence FGF-2-dependent signaling and SMC mitogenesis, on thrombin-induced FGF-2 release...
  42. ncbi High glucose enhances thrombin responses via protease-activated receptor-4 in human vascular smooth muscle cells
    Seema Dangwal
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat Dusseldorf, Dusseldorf, Germany
    Arterioscler Thromb Vasc Biol 31:624-33. 2011
    ..We investigated the effect of high glucose on expression and function of vascular thrombin receptors...
  43. ncbi Cellular adhesion molecules on vascular smooth muscle cells
    M Braun
    Institut fur Pharmakologie, Heinrich Heine Universitat, Dusseldorf, Germany
    Cardiovasc Res 41:395-401. 1999
    ..Therefore, ICAM-1 and VCAM-1 on smooth muscle cells may contribute to the inflammatory reaction in the vascular wall and may actively be involved in the progression and stability of atherosclerotic plaques...
  44. ncbi Transcriptional inhibition of protease-activated receptor-1 expression by prostacyclin in human vascular smooth muscle cells
    Robert Pape
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat Dusseldorf, Germany
    Arterioscler Thromb Vasc Biol 28:534-40. 2008
    ..Vascular injury is also associated with enhanced formation of PGE2 and PGI2 (prostacyclin). This study investigates whether PGI2 and PGE2 modify the expression of PAR-1 and the cellular response to thrombin in human SMC...
  45. ncbi Long-term-desensitization of prostacyclin receptors is independent of the C-terminal tail
    Andreas Hasse
    , , , Germany
    Biochem Pharmacol 65:1991-5. 2003
    ..These results demonstrated that long-term desensitization and sequestration of hIP-R did not depend on structures located in the hIP-R C-terminus...
  46. ncbi Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions
    Bernhard H Rauch
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Germany
    Arterioscler Thromb Vasc Biol 30:2434-42. 2010
    ..This study is the first to describe increased transcriptional expression of a functionally active P2Y12 in response to thrombin in human vascular smooth muscle cells (SMC)...
  47. ncbi Cardiospecific overexpression of the prostaglandin EP3 receptor attenuates ischemia-induced myocardial injury
    Melanie Martin
    , , Moorenstr 5, , Germany
    Circulation 112:400-6. 2005
    ..Cardioprotective actions of E-type prostaglandins may be mediated by this receptor subtype...
  48. ncbi Selective cyclooxygenase-2 inhibition upregulates renal cortical alpha V integrin expression
    Christoph Waldner
    Klinik fur Nephrologie und Rheumatologie, Heinrich Heine Universitat Dusseldorf, Germany
    Nephron Exp Nephrol 93:e72. 2003
    ....
  49. ncbi [Prasugrel, a new thienopyridine]
    K Schror
    Institutes für Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Universitatsstrasse 1, Geb 22 21, 40225 Dusseldorf
    Hamostaseologie 27:351-5. 2007
    ..Whether this is associated with an increased risk of bleeding will be seen from the first phase III clinical trial in PCI-patients. The first results are expected at the end of the year...
  50. ncbi Alternatively spliced human tissue factor (asHTF) is not pro-coagulant
    Petra Censarek
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Germany
    Thromb Haemost 97:11-4. 2007
    ..As expected, a marked pro-coagulant activity (FX activation, thrombin generation) was observed on the surface, in lysates, and on microparticles from HTF transfected cells. In contrast, no pro-coagulant activity of asHTF was observed...
  51. ncbi No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors
    Artur-Aron Weber
    , , , Germany
    Pharmacogenetics 12:581-3. 2002
    ..Thus, the present study does not provide evidence for an effect of HPA-1 polymorphism on the inter-individual variability in the platelet inhibitory effects of the three GPIIb/IIIa inhibitors approved for clinical use...
  52. ncbi Gene expression profile of the Gs-coupled prostacyclin receptor in human vascular smooth muscle cells
    Jutta Meyer-Kirchrath
    , , , , Moorenstr. 5, , Germany
    Biochem Pharmacol 67:757-65. 2004
    ..The present study identified genes not hitherto recognized to be targets of PGI2 action, providing further insight into its cAMP-mediated effects on SMC growth, migration and matrix secretion...
  53. ncbi Complex effects of different green tea catechins on human platelets
    Gereon Lill
    , , Moorenstr 5, , Germany
    FEBS Lett 546:265-70. 2003
    ....
  54. ncbi Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors
    Artur Aron Weber
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universitat, Universitatsklinikum Dusseldorf, Moorenstr 5, D 40225, Dusseldorf, Germany
    Thromb Res 106:25-9. 2002
    ..It is concluded that paradoxical platelet activation by abciximab is a rare (<2%) phenomenon. HPA-1 b/b genotype might be a contributing factor but clearly does not predict platelet activation by GP IIb/IIIa inhibitors...
  55. ncbi Clopidogrel inhibits platelet adhesion and platelet-dependent mitogenesis in vascular smooth muscle cells
    Alexander Hermann
    , , Moorenstrasse 5, , Germany
    Thromb Res 105:173-5. 2002
  56. ncbi ICAM-1 and p38 MAPK mediate fibrinogen-induced migration of human vascular smooth muscle cells
    Bernhard H Rauch
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum, Dusseldorf, Universitatsstr 1, 40225 Dusseldorf, Germany
    Eur J Pharmacol 577:54-7. 2007
    ..ICAM-1 antibodies inhibited fibrinogen-induced Akt and p38 phosphorylation. Thus fibrinogen stimulates human SMC migration through binding to ICAM-1 and activation of Akt and p38...
  57. ncbi Cerivastatin inhibits proliferation of interleukin-1 beta-induced rat mesangial cells by enhanced formation of nitric oxide
    Cornelia Blume
    Klinik für Nephrologie und Rheumatologie Medizinische Einrichtungen, Heinrich Heine Universitat, Moorenstrasse 5, 40225 Duesseldorf, Germany
    Eur J Pharmacol 485:1-10. 2004
    ..In conclusion, cerivastatin increased cytokine-induced iNOS and cyclooxygenase-2 expression, thus constituting NO-regulated growth inhibition of mesangial cells...
  58. ncbi CD40 ligand (CD40L) does not stimulate proliferation of vascular smooth muscle cells
    Alexander Hermann
    , , Germany
    Eur J Cell Biol 81:213-21. 2002
    ..Finally, sCD40L did not induce SMC migration. From these data it is concluded that CD40L activates mitogenic signalling and DNA synthesis but does not contribute to proliferation or migration of vascular SMC...
  59. ncbi Human cyclooxygenase-1b is not the elusive target of acetaminophen
    Petra Censarek
    , , Moorenstr. 5, , Germany
    Eur J Pharmacol 551:50-3. 2006
    ..Human cyclooxygenase-1bDeltaG was active but was not inhibited by acetaminophen. In conclusion, full length human cyclooxygenase-1b is clearly not the target of acetaminophen...
  60. ncbi Ammonia triggers exocytotic release of L-glutamate from cultured rat astrocytes
    Boris Gorg
    Clinic for Gastroenterology, Hepatology and Infectiology, Heinrich Heine University, Dusseldorf, Germany
    Glia 58:691-705. 2010
    ..It is concluded that ammonia triggers a prostanoid- and Ca(2+)-dependent glutamate exocytosis, which is essential for induction of ammonia-induced RNA oxidation...
  61. ncbi Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting
    Petra Censarek
    Institute für Pharmakologie and Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Germany
    Thromb Haemost 92:925-8. 2004
    ..Thus, the expression of a COX-2a protein corresponding to the 67 kDa COX-2 protein is not clear. However, the marked shifting from COX-2 to COX-2a in platelets from some patients after CABG is a striking finding...
  62. ncbi Membrane environment rather than tissue factor expression determines thrombin formation triggered by monocytic cells undergoing apoptosis
    Jan Julius Stampfuss
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Univesität Düsseldorf, Dusseldorf, Germany
    J Leukoc Biol 83:1379-81. 2008
    ..Externalization of negatively charged phospholipids represents the most important mechanisms for whole cells. Additional yet unknown mechanisms appear to be involved in the procoagulant actions of MPs derived from apoptotic monocytes...
  63. ncbi Analysis of a porcine EP3-receptor: cloning, expression and signal transduction
    J Meyer-Kirchrath
    Institut fur Pharmakologie, Heinrich Heine Universitat Dusseldorf, Germany
    Naunyn Schmiedebergs Arch Pharmacol 358:160-7. 1998
    ..The present data will now allow further studies on EP3 receptor-mediated signal transduction and its regulation...
  64. ncbi Rapid release of active tissue factor from human arterial smooth muscle cells under flow conditions
    Jan-Julius Stampfuss
    , , Germany
    Arterioscler Thromb Vasc Biol 26:e34-7. 2006
    ....
  65. ncbi The C-terminal peptide of thrombospondin-1 stimulates distinct signaling pathways but induces an activation-independent agglutination of platelets and other cells
    Simone Voit
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Moorenstr 5, Germany
    FEBS Lett 544:240-5. 2003
    ..Interestingly, 4N1-1 also stimulated activation-independent agglutination of different megakaryocytic and non-megakaryocytic cells. 4N1-1-induced cell agglutination but not platelet signaling was inhibited by anti-CD47 antibodies...
  66. ncbi Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of pro-MMP-2 to MMP-2: role of MMP-2 in factor Xa-induced DNA synthesis and matrix invasion
    Bernhard H Rauch
    Institut fur Pharmakologie und Klinische Pharmakologie, Universitatsklinikum Dusseldorf, Heinrich Heine Universitat, Dusseldorf, Germany
    Circ Res 90:1122-7. 2002
    ..Both might contribute to the mitogenic potency of FXa and FXa-stimulated matrix invasion of SMCs...
  67. ncbi Iloprost down-regulates the expression of the growth regulatory gene Cyr61 in human vascular smooth muscle cells
    Svenja Debey
    , , , Germany
    Eur J Pharmacol 474:161-4. 2003
    ..It is concluded that vasoprotective actions of prostacyclin in vivo may in part be due to inhibition of expression of the growth regulatory gene Cyr61 at sites of vascular lesions...